522 related articles for article (PubMed ID: 33142841)
21. The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers.
Eissa IR; Bustos-Villalobos I; Ichinose T; Matsumura S; Naoe Y; Miyajima N; Morimoto D; Mukoyama N; Zhiwen W; Tanaka M; Hasegawa H; Sumigama S; Aleksic B; Kodera Y; Kasuya H
Cancers (Basel); 2018 Sep; 10(10):. PubMed ID: 30261620
[TBL] [Abstract][Full Text] [Related]
22. Preinduced reovirus-specific T-cell immunity enhances the anticancer efficacy of reovirus therapy.
Groeneveldt C; Kinderman P; van Stigt Thans JJC; Labrie C; Griffioen L; Sluijter M; van den Wollenberg DJM; Hoeben RC; den Haan JMM; van der Burg SH; van Hall T; van Montfoort N
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35853671
[TBL] [Abstract][Full Text] [Related]
23. Synergistic antitumour effects of rapamycin and oncolytic reovirus.
Comins C; Simpson GR; Rogers W; Relph K; Harrington K; Melcher A; Roulstone V; Kyula J; Pandha H
Cancer Gene Ther; 2018 Jun; 25(5-6):148-160. PubMed ID: 29720674
[TBL] [Abstract][Full Text] [Related]
24. Potential for Improving Potency and Specificity of Reovirus Oncolysis with Next-Generation Reovirus Variants.
Mohamed A; Johnston RN; Shmulevitz M
Viruses; 2015 Dec; 7(12):6251-78. PubMed ID: 26633466
[TBL] [Abstract][Full Text] [Related]
25. Oncolytic Viruses in Cancer Treatment: A Review.
Lawler SE; Speranza MC; Cho CF; Chiocca EA
JAMA Oncol; 2017 Jun; 3(6):841-849. PubMed ID: 27441411
[TBL] [Abstract][Full Text] [Related]
26. Fighting Cancer with Viruses: Oncolytic Virus Therapy in China.
Wei D; Xu J; Liu XY; Chen ZN; Bian H
Hum Gene Ther; 2018 Feb; 29(2):151-159. PubMed ID: 29284308
[TBL] [Abstract][Full Text] [Related]
27. Oncolytic Viruses and the Immune System: The Dynamic Duo.
Lemos de Matos A; Franco LS; McFadden G
Mol Ther Methods Clin Dev; 2020 Jun; 17():349-358. PubMed ID: 32071927
[TBL] [Abstract][Full Text] [Related]
28. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
Thomas S; Kuncheria L; Roulstone V; Kyula JN; Mansfield D; Bommareddy PK; Smith H; Kaufman HL; Harrington KJ; Coffin RS
J Immunother Cancer; 2019 Aug; 7(1):214. PubMed ID: 31399043
[TBL] [Abstract][Full Text] [Related]
29. Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment.
Feola S; Russo S; Ylösmäki E; Cerullo V
Pharmacol Ther; 2022 Aug; 236():108103. PubMed ID: 34954301
[TBL] [Abstract][Full Text] [Related]
30. Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity.
Ilett EJ; Prestwich RJ; Kottke T; Errington F; Thompson JM; Harrington KJ; Pandha HS; Coffey M; Selby PJ; Vile RG; Melcher AA
Gene Ther; 2009 May; 16(5):689-99. PubMed ID: 19282847
[TBL] [Abstract][Full Text] [Related]
31. Determinants of the efficacy of viro-immunotherapy: A review.
de Graaf JF; Huberts M; Fouchier RAM; van den Hoogen BG
Cytokine Growth Factor Rev; 2020 Dec; 56():124-132. PubMed ID: 32919831
[TBL] [Abstract][Full Text] [Related]
32. Role of Myeloid Cells in Oncolytic Reovirus-Based Cancer Therapy.
Kumar V; Giacomantonio MA; Gujar S
Viruses; 2021 Apr; 13(4):. PubMed ID: 33920168
[TBL] [Abstract][Full Text] [Related]
33. Current landscape and perspective of oncolytic viruses and their combination therapies.
Su Y; Su C; Qin L
Transl Oncol; 2022 Nov; 25():101530. PubMed ID: 36095879
[TBL] [Abstract][Full Text] [Related]
34. Oncolytic Virotherapy in Solid Tumors: The Challenges and Achievements.
Jin KT; Du WL; Liu YY; Lan HR; Si JX; Mou XZ
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33546172
[TBL] [Abstract][Full Text] [Related]
35. Oncolytic Immunotherapy: Can't Start a Fire Without a Spark.
Muscolini M; Tassone E; Hiscott J
Cytokine Growth Factor Rev; 2020 Dec; 56():94-101. PubMed ID: 32826166
[TBL] [Abstract][Full Text] [Related]
36. The Oncolytic Herpes Simplex Virus Talimogene Laherparepvec Shows Promising Efficacy in Neuroendocrine Cancer Cell Lines.
Kloker LD; Berchtold S; Smirnow I; Schaller M; Fehrenbacher B; Krieg A; Sipos B; Lauer UM
Neuroendocrinology; 2019; 109(4):346-361. PubMed ID: 31280274
[TBL] [Abstract][Full Text] [Related]
37. Modulation of Reoviral Cytolysis (II): Cellular Stemness.
Bourhill T; Rohani L; Kumar M; Bose P; Rancourt D; Johnston RN
Viruses; 2023 Jun; 15(7):. PubMed ID: 37515162
[TBL] [Abstract][Full Text] [Related]
38. Advances in the clinical development of oncolytic viruses.
Li K; Zhao Y; Hu X; Jiao J; Wang W; Yao H
Am J Transl Res; 2022; 14(6):4192-4206. PubMed ID: 35836877
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic potential of oncolytic viruses in the era of precision oncology.
Kingsak M; Meethong T; Jongkhumkrong J; Cai L; Wang Q
Biomater Transl; 2023; 4(2):67-84. PubMed ID: 38283919
[TBL] [Abstract][Full Text] [Related]
40. Intratumoral Immunotherapy-Update 2019.
Hamid O; Ismail R; Puzanov I
Oncologist; 2020 Mar; 25(3):e423-e438. PubMed ID: 32162802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]